On World Hepatitis Day 2025, the World Health Organization (WHO) emphasized the importance of vaccination, early diagnosis, and treatment in combating hepatitis B and C, which are major causes of liver cancer. WHO highlighted that effective vaccines and curative treatments exist to prevent and manage hepatitis, with hepatitis B vaccination providing nearly 100% protection when administered soon after birth. The International Agency for Research on Cancer (IARC) has classified hepatitis D as carcinogenic to humans, similar to hepatitis B and C; hepatitis D only infects those already carrying hepatitis B and also contributes to liver cancer risk. WHO warned against transmission through the reuse of needles and sharing sharp instruments, urging the use of new needles to stay safe. The Nobel Prize organization noted that the discovery of the hepatitis C virus enabled blood testing and the development of lifesaving medicines, while Baruch Blumberg received the 1976 Nobel Prize for identifying hepatitis B’s cause and helping develop its vaccine. In New York City, newly reported chronic hepatitis B and C cases reveal disparities across gender, race, ethnicity, neighborhood, poverty, and age, underscoring ongoing public health challenges despite available care. Additionally, patients have raised concerns about funding challenges and job losses related to hepatitis care.